GLP-1 agonists are now widely prescribed for obesity management; however, their utility may be constrained by side effects, including common gastrointestinal side effects, such as nausea, vomiting, diarrhea, and constipation [103]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.